Clinical Trial Update: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating T cells expressing a fully-human anti-CD30 CAR for CD30-expressing lymphomas; study completed with posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enteropathy-associated T-cell Lymphoma
• Lymphoma Extranodal Nk-t-cell
• Lymphoma Large B-cell Diffuse
• Lymphoma Large-cell Anaplastic
• Lymphoma T-cell Peripheral

Drugs mentioned

• anti-CD30 chimeric antigen receptor T cells (CAR-T) (anti-CD30 CAR-T)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2022-05-25